About 11th Annual IMPACCT RWE Summit
As the abundance of data generated during routine healthcare grows, opportunities for use in clinical and observational research are increasing. It’s more important than ever for to identify RWE study needs at early stages drug development, as well as ensure clinical studies include regulatory criteria, appropriate protections for patients, and uphold data integrity.
This year, the 11th IMPACCT: RWE Summit returned to discuss the latest advances and exclusive case studies about the generation and application of RWE.
The summit allowed for a collaborative discussion platform, bringing together stakeholders from functions across clinical development, RWE, RWD, analytics, epidemiologists, medical affairs and more!
It’s now critical for drug developers, clinical trial sponsors, and associated stakeholders to adapt and expand their RWE strategies. In October, attendees met to overcome critical challenges in generating and implementing real-world evidence to enhance clinical trial design & support regulatory submission and decision-making.
What You Missed In 2023
Exploring the end-to-end uses of tokenization for collecting, linking & analyzing data to generate RWE for payers and HTA bodies with Otsuka
Navigating heterogeneity in the global regulatory landscape to utilize RWE to support regulatory submissions in every jurisdiction with Bristol Myers Squibb, Eisai & The Danish Medicines Agency
Overcoming challenges in RWD data quality to produce high quality RWE for informing clinical development decision making and trials with NICE, Pfizer & The Crohn’s & Colitis Foundation
Pioneering clinical trials with tokenization approaches, utilizing synthetic control arms and mitigating safety risks for RWD with Sanofi & Gilead Sciences
Leveraging RWE to understand target patient populations and drive diversity, equity and inclusion to meet regulatory guidance with Pfizer & Alexion Pharmaceuticals